ArticleClinical and experimental immunology2014
Intravenous immunoglobulin for Alzheimer's disease.
Article in Clinical and experimental immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A phase 3 trial of IV immunoglobulin for Alzheimer disease.Neurology · 2017Trial
- Genetic evidence suggests a protective role of immunoglobulin M in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Immune cells in Alzheimer's disease: insights into pathogenesis and potential therapeutic targets.Medical review (2021) · 2025Review
- Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.European journal of clinical pharmacology · 2022Review
- Decreased immunoglobulin G in brain regions of elder female APOE4-TR mice accompany with Aβ accumulation.Immunity & ageing : I & A · 2019Article
- Neuroprotective effects of intravenous immunoglobulin are mediated through inhibition of complement activation and apoptosis in a rat model of sepsis.Intensive care medicine experimental · 2017Article
- The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers.Oncotarget · 2017Article
- Importance of neonatal immunoglobulin transfer for hippocampal development and behaviour in the newborn pig.PloS one · 2017Article
- Effects of Acyclovir and IVIG on Behavioral Outcomes after HSV1 CNS Infection.Behavioural neurology · 2017Article
- Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2016Article
- Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2016Article
- Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.